BruceJGiantonioMD
Oncology • Philadelphia, PAAssociate Professor, Medicine, Perelman School of Medicine
Dr. Giantonio is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3400 Spruce St
15 Penn Tower
Philadelphia, PA 19104Phone+1 215-662-3914- Is this information wrong?
Education & Training
Temple University HospitalFellowship, Hematology and Medical Oncology, 1990 - 1993
University of Vermont Medical CenterResidency, Internal Medicine, 1987 - 1990
Georgetown University School of MedicineClass of 1987
Certifications & Licensure
MA State Medical License 2017 - 2026
PA State Medical License 1990 - 2021
ME State Medical License 2020 - 2021
VT State Medical License 1987 - 1990- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 2000 Nov 01
- Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated Start of enrollment: 2001 Sep 01
- Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Start of enrollment: 2003 Oct 15
- Join now to see all
Publications & Presentations
PubMed
- Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer.Joy X Jarnagin, Anurag Saraf, Islam Baiev, Gary Chi, Emily E van Seventer, Amirkasra Mojtahed, Jill N Allen, Jeffrey W Clark, Lawrence Blaszkowsky, Bruce J Giantonio, ...> ;JAMA Network Open. 2023 Nov 1
- Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma.Ofer Margalit, Einat Shacham-Shmueli, Gal Strauss, Yu-Xiao Yang, Yaacov R Lawrence, Alon Ben Nun, Idan Levy, Kim A Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce...> ;Cancer Investigation. 2023 Sep 1
- 1 citationsBevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Coope...Bruce J Giantonio, Paul J Catalano, Neal J Meropol, Peter J O'Dwyer, Edith P Mitchell, Steven R Alberts, Michael A Schwartz, Al B Benson 3rd> ;Journal of Clinical Oncology. 2023 Jul 20
- Join now to see all
Authored Content
- A New Look at the International Duration Evaluation of Adjuvant Therapy (IDEA) Classification—Defining Novel Predictive and Prognostic Markers in Stage III Colon CancerMay 2018
- A New Look at the International Duration Evaluation of Adjuvant Therapy (IDEA) Classification—Defining Novel Predictive and Prognostic Markers in Stage III Colon CancerMay 2018
- A New Look at the International Duration Evaluation of Adjuvant Therapy (IDEA) Classification—Defining Novel Predictive and Prognostic Markers in Stage III Colon CancerMay 2018
Press Mentions
Donegal Woman Finally Starts Lifesaving Cancer Treatment in USAugust 18th, 2021
Racial Disparities in Colon Cancer Survival PersistDecember 30th, 2018
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
